<DOC>
	<DOC>NCT00878670</DOC>
	<brief_summary>In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.</brief_summary>
	<brief_title>Investigation of Efficacy and Safety of EPOGAM</brief_title>
	<detailed_description>Patients with atopic dermatitis will receive EPOGAM 1000 for 12 weeks. Clinical symptoms of the disease will be assessed using the SCORAD score. Dihomo-gamma-linolic acid levels in the blood will be measured with GC-MS.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Efamol</mesh_term>
	<criteria>atopic dermatitis since at least 2 months (criteria after Hanifin and Rajka, 1980) men or women aged 2 45 years women of childbearing age using contraception informed consent of the patient or of the parents psychiatric disorder abuse of drugs or alcohol chronic dermatosis glaucoma, cataract or ocular herpes simplex Immune deficiency Immunological diseases clinical relevant changes in laboratory parameters congenital diseases scabies, infections with dermathophytae, HIVassociated dermatosis malignant diseases metabolic diseases parasites patients enrolled in other studies progredient, systemic diseases pregnancy and lactation severe internistic diseases organ transplantation in the medical history hypersensitivity against an ingredient of the study medication</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>